Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
J Alzheimers Dis ; 91(3): 1073-1083, 2023.
Article in English | MEDLINE | ID: mdl-36565112

ABSTRACT

BACKGROUND: Plasminogen activator inhibitor-1 (PAI-1), an inhibitor of fibrinolysis that is associated with adiposity, has been implicated in Alzheimer's disease (AD) pathogenesis. However, whether circulating PAI-1 levels are altered during preclinical AD remains unclear. OBJECTIVE: To measure plasma PAI-1 levels in cognitively normal cerebrospinal fluid (CSF) AD biomarker positive and biomarker negative participants and to examine the association of plasma PAI-1 levels with CSF AD biomarkers and Mini-Mental State Examination (MMSE) scores. METHODS: In this cross-sectional study, plasma PAI-1 levels were measured in 155 cognitively normal (Clinical Dementia Rating, CDR 0) non-obese older adults. 29 men and 26 women were classified as preclinical AD by previously established CSF tau/Aß42 criteria. All analyses were sex stratified due to reported sex differences in PAI-1 expression. RESULTS: Plasma PAI-1 levels were associated with body mass index (BMI) but not age in men and women. In men, plasma PAI-1 levels and BMI were lower in preclinical AD compared to control. Plasma PAI-1 levels were positively associated with CSF amyloid-ß42 (Aß42) and CSF Aß42/Aß40 and negatively associated with CSF tau/Aß42, while BMI was positively associated with CSF Aß42 and negatively associated with CSF p-tau181 and CSF tau/Aß42. In women, plasma PAI-1 levels and BMI were similar between preclinical AD and control and were not associated with CSF AD biomarkers. For men and women, plasma PAI-1 levels and BMI were not associated with MMSE scores. CONCLUSION: These findings suggest that there are significant sex differences in the systemic metabolic changes seen in the preclinical stage of AD.


Subject(s)
Alzheimer Disease , Female , Humans , Male , Aged , Alzheimer Disease/diagnosis , Alzheimer Disease/cerebrospinal fluid , Body Mass Index , Amyloid beta-Peptides/cerebrospinal fluid , Plasminogen Activator Inhibitor 1 , Cross-Sectional Studies , tau Proteins/cerebrospinal fluid , Biomarkers/cerebrospinal fluid , Peptide Fragments/cerebrospinal fluid
2.
Front Mol Biosci ; 7: 584228, 2020.
Article in English | MEDLINE | ID: mdl-33634165

ABSTRACT

Human Genome Wide Association Studies found a significant risk of Type 2 Diabetes Mellitus (T2DM) in single nucleotide polymorphisms in the cdkal1 gene. The cdkal1 gene is remote from the insulin gene and with the surprising function of a specific tRNA modification. Population studies and case control studies acquired evidences of the connection between Cdkal1 protein and insulin production over the years. To obtain biochemical proofs directly linking potential SNPs to their roles in insulin production and availability is challenging, but the development of Cdkal1 knock out mice and knock out cell lines made it possible to extend our knowledge towards therapeutic field of diabetic research. Supporting the evidences, here we show that knock down of the cdkal1 gene using small interfering and short hairpin RNA in the NIT-1 cell line, a ß-cell line inducible for insulin resulted in reduced levels of cdkal1 and mature insulin mRNAs, increased the level of precursor insulin mRNA, decreased Cdkal1 and insulin proteins, and diminished modification of tRNALys3 from t6A37 to ms2t6A37, the specified function of Cdkal1. tRNALys3 lacking ms2- is incapable of establishing sufficient hydrogen bonding energy and hydrophobic stabilization to decode the wobble codon AAG.

3.
Alzheimers Dement (Amst) ; 11: 646-653, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31517027

ABSTRACT

INTRODUCTION: Lipocalin-2 is an acute-phase protein with pleotropic functions that has been implicated in several diseases including Alzheimer's disease (AD). However, it is unknown if circulating lipocalin-2 levels are altered in the preclinical stage of AD, where AD pathology has accumulated but cognition remains relatively intact. METHODS: In this cross-sectional study, we used an immunoassay to measure plasma lipocalin-2 levels in cognitively normal (Clinical Dementia Rating 0) elderly individuals. 38 of 156 subjects were classified as preclinical AD by cerebrospinal fluid criteria. RESULTS: Plasma lipocalin-2 levels were higher in preclinical AD compared with control subjects and associated with cerebrospinal fluid amyloid-beta42 levels but not cerebrospinal fluid tau or phosphorylated-tau181 levels. Exploratory analyses revealed that plasma lipocalin-2 was associated with executive function but not episodic memory. DISCUSSION: Collectively, these results raise the possibility that circulating lipocalin-2 is involved early in AD pathogenesis and may represent an early blood biomarker of amyloid-beta pathology.

4.
RNA Biol ; 15(4-5): 537-553, 2018.
Article in English | MEDLINE | ID: mdl-28812932

ABSTRACT

A simple post-transcriptional modification of tRNA, deamination of adenosine to inosine at the first, or wobble, position of the anticodon, inspired Francis Crick's Wobble Hypothesis 50 years ago. Many more naturally-occurring modifications have been elucidated and continue to be discovered. The post-transcriptional modifications of tRNA's anticodon domain are the most diverse and chemically complex of any RNA modifications. Their contribution with regards to chemistry, structure and dynamics reveal individual and combined effects on tRNA function in recognition of cognate and wobble codons. As forecast by the Modified Wobble Hypothesis 25 years ago, some individual modifications at tRNA's wobble position have evolved to restrict codon recognition whereas others expand the tRNA's ability to read as many as four synonymous codons. Here, we review tRNA wobble codon recognition using specific examples of simple and complex modification chemistries that alter tRNA function. Understanding natural modifications has inspired evolutionary insights and possible innovation in protein synthesis.


Subject(s)
Adenosine/metabolism , Genetic Code , Inosine/metabolism , Protein Biosynthesis , RNA Processing, Post-Transcriptional , RNA, Transfer/chemistry , Adenosine/genetics , Archaea/genetics , Archaea/metabolism , Bacteria/genetics , Bacteria/metabolism , Base Pairing , Deamination , Eukaryota/genetics , Eukaryota/metabolism , Evolution, Molecular , Inosine/genetics , Models, Molecular , Nucleic Acid Conformation , RNA, Transfer/genetics , RNA, Transfer/metabolism
5.
Enzymes ; 41: 1-50, 2017.
Article in English | MEDLINE | ID: mdl-28601219

ABSTRACT

The posttranscriptional modifications of tRNA's anticodon stem and loop (ASL) domain represent a third level, a third code, to the accuracy and efficiency of translating mRNA codons into the correct amino acid sequence of proteins. Modifications of tRNA's ASL domain are enzymatically synthesized and site specifically located at the anticodon wobble position-34 and 3'-adjacent to the anticodon at position-37. Degeneracy of the 64 Universal Genetic Codes and the limitation in the number of tRNA species require some tRNAs to decode more than one codon. The specific modification chemistries and their impact on the tRNA's ASL structure and dynamics enable one tRNA to decode cognate and "wobble codons" or to expand recognition to synonymous codons, all the while maintaining the translational reading frame. Some modified nucleosides' chemistries prestructure tRNA to read the two codons of a specific amino acid that shares a twofold degenerate codon box, and other chemistries allow a different tRNA to respond to all four codons of a fourfold degenerate codon box. Thus, tRNA ASL modifications are critical and mutations in genes for the modification enzymes and tRNA, the consequences of which is a lack of modification, lead to mistranslation and human disease. By optimizing tRNA anticodon chemistries, structure, and dynamics in all organisms, modifications ensure translational fidelity of mRNA transcripts.


Subject(s)
Anticodon/chemistry , Anticodon/genetics , Genetic Code , Protein Biosynthesis , RNA Processing, Post-Transcriptional , RNA, Transfer/chemistry , RNA, Transfer/genetics , Amino Acid Sequence , Codon/genetics , Humans
6.
Biomolecules ; 7(1)2017 03 16.
Article in English | MEDLINE | ID: mdl-28300792

ABSTRACT

RNAs are central to all gene expression through the control of protein synthesis. Four major nucleosides, adenosine, guanosine, cytidine and uridine, compose RNAs and provide sequence variation, but are limited in contributions to structural variation as well as distinct chemical properties. The ability of RNAs to play multiple roles in cellular metabolism is made possible by extensive variation in length, conformational dynamics, and the over 100 post-transcriptional modifications. There are several reviews of the biochemical pathways leading to RNA modification, but the physicochemical nature of modified nucleosides and how they facilitate RNA function is of keen interest, particularly with regard to the contributions of modified nucleosides. Transfer RNAs (tRNAs) are the most extensively modified RNAs. The diversity of modifications provide versatility to the chemical and structural environments. The added chemistry, conformation and dynamics of modified nucleosides occurring at the termini of stems in tRNA's cloverleaf secondary structure affect the global three-dimensional conformation, produce unique recognition determinants for macromolecules to recognize tRNAs, and affect the accurate and efficient decoding ability of tRNAs. This review will discuss the impact of specific chemical moieties on the structure, stability, electrochemical properties, and function of tRNAs.


Subject(s)
Nucleic Acid Conformation , Nucleosides/chemistry , RNA, Transfer/chemistry , RNA, Transfer/metabolism , Anticodon/chemistry , Methylation , Stereoisomerism
SELECTION OF CITATIONS
SEARCH DETAIL
...